Actavia Life Sciences Company Description

Actavia Life Sciences, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma.

It is developing RASP-201, a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase, a pathway that blocks differentiation and confers a poor prognosis to AML; and RASP-301, an NCE for NPM1, currently at the pre-clinical stage to treat refractory AML with reduced toxicity.

The company was formerly known as Rasna Therapeutics, Inc. and changed its name to Actavia Life Sciences, Inc. in October 2023.

Actavia Life Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.

Actavia Life Sciences, Inc.

Country	United States
Founded	2013
Industry	Biotechnology
Sector	Healthcare
Employees	1

Contact Details

Address: 5 Penn Plaza New York, Nevada 10001 United States
Phone	646 396 4087
Website	rasna.com

Stock Details

Ticker Symbol	RASP
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	October - September
Reporting Currency	USD
ISIN Number	US7538881068
SIC Code	2836

Key Executives

Name	Position
Keeren Shah	Chief Financial Officer
Willy Jules Simon	Executive Chairman